Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl]benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity

Molecular Pharmacology

Volumn 75, Issue 6, 2009, Pages 1364-1373

  Yu, Le ^a,b   Wu, William Ka Kei ^a   Zhi, Jie Li ^a,b   Qi, Cai Liu ^a   Hai, Tao Li ^a   Ya, Chun Wu ^a   Chi, Hin Cho ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ADENOSINE TRIPHOSPHATASE; CYCLOOXYGENASE 2; DOXORUBICIN; GLYCOPROTEIN P; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN E2; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADENOSINE TRIPHOSPHATASES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESOPHAGEAL NEOPLASMS; GENE KNOCKDOWN TECHNIQUES; HUMANS; INDOMETHACIN; NF-KAPPA B; P-GLYCOPROTEIN; PYRAZOLES; RNA, SMALL INTERFERING; SULFONAMIDES;

EID: 66849101753     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.108.053546     Document Type: Article

References (40)

1. Akita H, Doki Y, Miyata H, Hirao T, Yano M, Takachi K, Miyashiro I, Sasaki Y, Ishikawa O, Ohigashi H, and Imaoka S (2006) Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol 93:401-409.
2. Awara WM, El-Sisi AE, El-Sayad ME, and Goda AE (2004) The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?. Pharmacol Res 50:487-498. (Pubitemid 39349050)
3. Blot WJ and McLaughlin JK (1999) The changing epidemiology of esophageal cancer. Semin Oncol 26:2-8. (Pubitemid 29529530)
4. Corley DA, Kerlikowske K, Verma R, and Buffler P (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124:47-56. (Pubitemid 36055338)
5. David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, and Nelson WG (2000) Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol 17:1077-1086.
6. Dorai T and Aggarwal BB (2004) Role of chemoprevention agents in cancer therapy. Cancer Lett 215:129-140. (Pubitemid 39370030)
7. Draper MP, Martell RL, and Levy SB (1997) Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br J Cancer 75:810-815. (Pubitemid 27110695)
8. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, Kavanagh K, Verhaegen S, O'Loughlin CM, NicAmhlaoibh R, et al. (1998) Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 34:1250-1259. (Pubitemid 28342118)
9. Gillet JP, Efferth T, and Remacle J (2007) Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775:237-262. (Pubitemid 46899341)
10. Goldberg Y, Nassif II, Pittas A, Tsai LL, Dynlacht BD, Rigas B, and Shiff SJ (1996) The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893-901. (Pubitemid 26072275)
11. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, and Sakurai K (2003) Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol 23:665-672.
12. Helleberg L (1981) Clinical pharmacokinetics of indomethacin. Clin Pharmacokinet 6:245-258. (Pubitemid 12219231)
13. Hu Y, Lam KY, Wan TS, Fang W, Ma ES, Chan LC, and Srivastava G (2000) Establishment and characterization of HKESC-1, a new cancer cell line from human esophageal squamous cell carcinoma. Cancer Genet Cytogenet 118:112-120. (Pubitemid 30169212)
14. Hu YC, Lam KY, Law SY, Wan TS, Ma ES, Kwong YL, Chan LC, Wong J, and Srivastava G (2002) Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human esophageal squamous cell carcinoma cell lines. Cancer Genet Cytogenet 135:120-127. (Pubitemid 34786763)
15. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, and Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5:1418-1423.
16. Kosugi S, Kanda T, Nakagawa S, Ohashi M, Nishimaki T, and Hatakeyama K (2005) Efficacy and toxicity of fluorouracil, doxorubicin, and cisplatin/nedaplatin treatment as neoadjuvant chemotherapy for advanced esophageal carcinoma. Scand J Gastroenterol 40:886-892. (Pubitemid 41117012)
17. Lee A, Frischer J, Serur A, Huang J, Bae JO, Kornfield ZN, Eljuga L, Shawber CJ, Feirt N, Mansukhani M, et al. (2006) Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res 66:4378-4384.
18. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, and Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311. (Pubitemid 30151999)
19. Mimeault M, Hauke R, and Batra SK (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-691.
20. Nakanishi C and Toi M (2005) Nuclear factor-kappa B inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309. (Pubitemid 40488635)
21. Nakanishi O, Baba M, Saito A, Yamashita T, Sato W, Abe H, Fukazawa N, Suzuki T, Sato S, Naito M, et al. (1997) Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines. Oncol Res 9:61-69. (Pubitemid 127825886)
22. Naritaka Y, Ogawa K, Shimakawa T, Wagatsuma Y, Hamaguchi K, Konno S, Katsube T, Yagawa H, Aiba M, and Ide H (2004) Case report: a young woman with advanced esophageal cancer showing pathological complete response to neoadjuvant chemotherapy (CDDP, 5-FU and ADM). Anticancer Res 24:2385-2389. (Pubitemid 39166321)
23. O'Connor R, Heenan M, Connolly L, Larkin A, and Clynes M (2004) Increased anti-tumour efficacy of doxorubicin when combined with sulindac in a xenograft model of an MRP-1-positive human lung cancer. Anticancer Res 24:457-464. (Pubitemid 38623120)
24. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, and Reinhardt D (2005) Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 312:346-354. (Pubitemid 40096488)
25. Roller A, Bähr OR, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, and Weller M (1999) Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun 259:600-605. (Pubitemid 29335579)
26. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, and Tsuruo T (1995) Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother Pharmacol 35:271-277.
27. Shao J, Fujiwara T, Kadowaki Y, Fukazawa T, Waku T, Itoshima T, Yamatsuji T, Nishizaki M, Roth JA, and Tanaka N (2000) Overexpression of the wide-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19:726-736. (Pubitemid 30107703)
28. Shimakawa T, Naritaka Y, Asaka S, Isohata N, Murayama M, Konno S, Yoshimatsu K, Shiozawa S, Katsube T, and Ogawa K (2008) Neoadjuvant chemotherapy (FAP) for advanced esophageal cancer. Anticancer Res 28:2321-2326.
29. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, et al. (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317. (Pubitemid 46218723)
30. Stoner GD and Gupta A (2001) Etiology and chemoprevention of esophageal squamous cell carcinoma. Carcinogenesis 22:1737-1746. (Pubitemid 33064837)
31. Stoner GD, Qin H, Chen T, Carlton PS, Rose ME, Aziz RM, and Dixit R (2005) The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 26:1590-1595. (Pubitemid 41236052)
32. Tew WP, Kelsen DP, and Ilson DH (2005) Targeted therapies for esophageal cancer. Oncologist 10:590-601. (Pubitemid 41429122)
33. Thomas H and Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159-165. (Pubitemid 36437822)
34. van Wijngaarden J, van Beek E, van Rossum G, van der Bent C, Hoekman K, van der Pluijm G, van der Pol MA, Broxterman HJ, van Hinsbergh VW, and Löwik CW (2007) Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-KappaB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43:433-442. (Pubitemid 46123984)
35. Wobst A, Audisio RA, Colleoni M, and Geraghty JG (1998) Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol 9:951-962. (Pubitemid 28496702)
36. Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T, Ohue M, Ohigashi H, et al. (2006) Preoperative chemotherapy for clinically node-positive patients with squamous cell carcinoma of the esophagus. Dis Esophagus 19:158-163. (Pubitemid 43756662)
37. Zatelli MC, Luchin A, Piccin D, Tagliati F, Bottoni A, Vignali C, Bondanelli M, and degli Uberti EC (2005) Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J Clin Endocrinol Metab 90:5754-5760.
38. Zatelli MC, Luchin A, Tagliati F, Leoni S, Piccin D, Bondanelli M, Rossi R, and degli Uberti EC (2007) Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. Endocr Relat Cancer 14:1029-1038.
39. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, and Schrör K (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198-204. (Pubitemid 29062978)
40. Zrieki A, Farinotti R, and Buyse M (2008) Cyclooxygenase inhibitors down-regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res 25:1991-2001.